An experimental drug drove people to lose 23% of their body weight. It’s still seen as a disappointment
Novo Nordisk’s latest attempt in weight loss, a combination drug called CagriSema, matched the bar set by Lilly’s currently ...
Novo Nordisk new obesity therapy CagriSema outperforms semaglutide in Phase 3 trial
Novo Nordisk’s (NVO) next-gen weight loss therapy, CagriSema, caused up to ~23% of weight loss compared to ~16% of weight ...
Hosted on MSN1d
Bipolar and Stress: How to Stop the Snowball Effect
Minor stressors don’t have to spiral out of control. Learn strategies to manage daily pressures effectively. Allow me to set ...